Barclays PLC Buys 183,861 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Barclays PLC boosted its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 196.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 277,682 shares of the company’s stock after acquiring an additional 183,861 shares during the period. Barclays PLC owned 0.16% of X4 Pharmaceuticals worth $185,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the 3rd quarter worth $30,000. SG Americas Securities LLC acquired a new stake in X4 Pharmaceuticals in the third quarter valued at about $37,000. XTX Topco Ltd bought a new position in X4 Pharmaceuticals in the second quarter valued at about $65,000. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares during the last quarter. Finally, Jane Street Group LLC raised its position in X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after purchasing an additional 126,296 shares during the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.49 on Thursday. The firm has a market cap of $83.21 million, a PE ratio of -5.42 and a beta of 0.14. The stock’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $0.61. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals, Inc. has a 1 year low of $0.26 and a 1 year high of $1.60.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on XFOR shares. Stifel Nicolaus lowered their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.